Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
{{output}}
Enfortumab vedotin (NECTIN4-ADC), a NECTIN4-targeting antibody-drug conjugate, has shown substantial efficacy in urothelial carcinoma, yet primary and acquired resistance remain major barriers to durable benefit. By integrating paired spatial transcriptomic pr... ...
